Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Momenta Pharmaceuticals received early financing of $19.0M on 2003-05-21.
| Series | Round size | Date |
|---|---|---|
| Series B | $19M | 05/2003 |
| Series C | $20.5M | 03/2004 |
| Investors | Security type |
|---|---|
| Polaris Partners | Series B |
| Cardinal Partners | Series B |
| Atlas Venture | Series B |
| Santo Carbone Life Science Consultant | Series B |
| Polaris Partners | Series C |
| Mithra Ventures | Series C |
| Cardinal Partners | Series C |
| Atlas Venture | Series C |
| Santo Carbone Life Science Consultant | Series C |
Momenta Pharmaceuticals's top competitor, Alnylam Pharmaceuticals, earned an annual revenue of $2.2B.
Momenta Pharmaceuticals's smallest competitor is Cylene Pharmaceuticals with revenue of $284.9K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | - | $2.2B | 1,323 | - |
| Tetraphase Pharmaceuticals | - | $7.4M | 67 | - |
| Infinity Pharmaceuticals | - | $2.6M | 100 | - |
| Lexicon Pharmaceuticals | - | $31.1M | 225 | - |
| Dabur Research Foundation | - | $40.0M | 1,000 | - |
| Constellation Pharmaceuticals | - | $4.7M | 82 | - |
| Merrimack Pharmaceuticals | - | $102.8M | 426 | - |
| Absorption Systems | - | $26.0M | 163 | - |
| Cylene Pharmaceuticals | - | $284.9K | 3 | - |
| EyeGate Pharmaceuticals | - | $767,000 | 30 | - |
Zippia gives an in-depth look into the details of Momenta Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Momenta Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Momenta Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Momenta Pharmaceuticals. The data presented on this page does not represent the view of Momenta Pharmaceuticals and its employees or that of Zippia.
Momenta Pharmaceuticals may also be known as or be related to MOMENTA PHARMACEUTICALS INC, Momenta Pharmaceuticals, Momenta Pharmaceuticals Inc and Momenta Pharmaceuticals, Inc.